They have developed unique Point of Care Device, which shall revolutionize the diagnosis of Acute Myocardial Infarction (AMI), as it detects the biomarker in under 4 minutes. Their nanotechnology based technology platform is capable of diagnosing any biomarker and in any medium as it is based on Nanoplasmonic  Plasmonic Resonance. Both clinically proven device and the technology platform are available for licensing/partnering.

Aagami feels that the Asian region companies are uniquely suited for this as they are growing at a much rapid pace in their home markets and nowadays playing a larger role in markets across the world. Also the Asians are quite willing to in-license new technologies, that will enable them to compete with traditional big players of the West.